Empagliflozin Inhibits OSCC Proliferation and Migration by Suppressing SLC2A3 and NLRP3
Abstract
Aim: High glucose and inflammation facilitate oral squamous cell carcinoma (OSCC) progression.The glucose transporter solute carrier family 2 member 3 (SLC2A3) and the nucleotide-binding oligomerization domain, leucine-rich repeat-containing family pyrin domain containing 3 (NLRP3), contribute to chronic inflammation and poor prognosis.This study investigates the regulatory effects of the antidiabetic drug empagliflozin (emp) on SLC2A3 and NLRP3 in OSCC and their impact on cancer cell growth. Materials and Methods:Human OSCC cell lines, SCCL-MT1 and UPSI-SCC-131, were cultured in Dulbecco's Modified Eagle Medium with supplements.Emp, lipopolysaccharide, and adenosine triphosphate were used for treatments.Real-time polymerase chain reaction quantified SLC2A3 and NLRP3 expressions.Enzyme-linked immunosorbent assay measured interleukin-1beta (IL-1β) levels, and cell proliferation was assessed using the xCELLigence system.Migration was evaluated via a scratch wound assay.Protein-protein interactions were predicted using the STRING database.Data analysis was conducted using GraphPad Prism.Results: Emp, an SGLT2 inhibitor, significantly reduced SLC2A3 (p<0.0001,p=0.0002; respectively) and NLRP3 expression (p=0.0008;p=0.0006; respectively), leading to decreased IL-1β release (p=0.0190,p<0.0001; respectively), proliferation (p=0.024;p<0.0001; respectively), and migration (p=0.0021;p=0.0004, respectively) in SCCL-MT1 and UPSI-SCC131 OSCC cell lines.These findings suggest emp's…
Read the paper
Related studies
- The Role of AMPK Activation for Cardioprotection in Doxorubicin-Induced Cardiotoxicity
- Hypoglycemic medicines in the treatment of Alzheimer’s disease: Pathophysiological links between AD and glucose metabolism
- Isorhamnetin Reduces Glucose Level, Inflammation, and Oxidative Stress in High-Fat Diet/Streptozotocin Diabetic Mice Model
- Modulating Sirtuin Biology and Nicotinamide Adenine Diphosphate Metabolism in Cardiovascular Disease—From Bench to Bedside
- Characterization of the SGLT2 Interaction Network and Its Regulation by SGLT2 Inhibitors: A Bioinformatic Analysis
- Early Treatment with Empagliflozin and GABA Improves β-Cell Mass and Glucose Tolerance in Streptozotocin-Treated Mice
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.